https://orcid.org/0000-0002-9684-4042
Figures
Abstract
Objective
Gonadotropin-releasing hormone agonist (GnRHa) treatment improves the potential for gaining height in patients with central precocious puberty (CPP). However, most studies have focused on girls because CPP in boys is relatively rare. Therefore, we aimed to determine the effect of GnRHa treatment on auxological outcomes in boys with CPP.
Methods
Eighty-five boys with CPP were treated with leuprolide or triptorelin acetate 3.75 mg over 2 years. Anthropometry, bone age, sexual maturity rating, and predicted adult height (PAH) were assessed every 6 months. Furthermore, 20 boys were followed up after treatment discontinuation until achievement of the final adult height (FAH).
Results
The mean chronological age (CA) and bone age (BA) of the patients with CPP at treatment initiation were 9.5 ± 0.5 years and 11.7 ± 0.9 years, respectively. The mean duration of treatment was 2.87 ± 0.63 years. The PAH at treatment initiation was 172.1 cm (-0.23 ± 1.05 PAH standard deviation score). The PAH at treatment discontinuation (176.2 ± 6.6 cm) was significantly higher than the pretreatment PAH. In addition, the mean final adult height in the 20 boys who were followed up after discontinuation of treatment was 173.4 ± 5.8 cm, which was significantly higher than the initial PAH (170.1 ± 4.5 cm; p = 0.006). In multivariate analysis, the height gain (the difference between the FAH and PAH at treatment initiation) significantly correlated with the target height.
Citation: Shim YS, Lim KI, Lee HS, Hwang JS (2020) Long-term outcomes after gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty. PLoS ONE 15(12): e0243212. https://doi.org/10.1371/journal.pone.0243212
Editor: Hubert Vaudry, Universite de Rouen, FRANCE
Received: April 1, 2020; Accepted: November 17, 2020; Published: December 10, 2020
Copyright: © 2020 Shim et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the manuscript and its Supporting Information files.
Funding: HS Lee received the new faculty research grant from Ajou University School of Medicine, URL: http://medicine.ajou.ac.kr/, Grant number M-2016-C0460-00033. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: None of the authors have any conflict of interest to disclose. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.
Introduction
Precocious puberty (PP) refers to the development of secondary sexual characteristics before the age of 8 and 9 years in girls and boys, respectively [1]. Central precocious puberty (CPP) is caused by early maturation of the hypothalamic–pituitary–gonadal axis. It is caused by organic brain disorders such as tumors, hemorrhage, or infection in approximately 40%–50% boys with CPP [1]. It can also be idiopathic. The main goal of treatment for CPP is to suppress the gonadal sex steroid secretion effectively to stop premature sexual maturation. Additionally, the treatment aims to preserve the potential to achieve acceptable adult height in each individual based on genetic determinants by suppressing the accelerated skeletal advancement [1].
Currently, gonadotropin-releasing hormone agonists (GnRHa) have been used in the treatment of CPP [1–5]. Although extensive research has been conducted in girls with CPP, very few studies have assessed the long-term outcome of GnRHa treatment in boys with CPP because the incidence of CPP in boys is approximately 10 times lower than that in girls [6–10]. Therefore, this study aimed to determine the effects of GnRHa treatment on auxological outcomes in boys with CPP.
Subjects and methods
Patients
Clinical records of 85 boys with CPP who were treated with GnRHa for >2 years at Ajou University Hospital, South Korea from 2007 to 2017 were reviewed. CPP was diagnosed based on the following criteria: (1) objective testicular volume ≥4 mL before 9 years of age, (2) advanced bone age (BA) >1 year above the chronological age (CA), and (3) peak values of pubertal luteinizing hormone (LH) (cutoff value: ≥5 IU/L) achieved during a GnRH stimulation test. Plasma thyroxine and thyroid-stimulating hormone levels were also measured to exclude hypothyroidism. Boys with brain tumor, congenital adrenal hyperplasia, hypothyroidism, or those who received cranial irradiation were excluded from the study. Patients who were treated with growth hormones were also excluded. Of the 85 boys with CPP, 76 boys underwent magnetic resonance imaging (MRI) of the hypothalamic–pituitary area. The other 9 patients refused to undergo MRI. MRI abnormality was not detected in 68 subjects. Brain lesions not definitively related to CPP were found in 8 boys. These included pituitary hyperplasia (n = 4), Rathke’s cleft cyst (n = 2), pineal cyst (n = 1), and arachnoid cyst (n = 1). However, none of the 8 boys had any neurologic symptoms such as headache or seizure.
The standard treatment regimen was subcutaneous administration of leuprolide or triptorelin acetate 3.75 mg every 4 weeks. Twenty-four patients were treated with leuprolide acetate and the other 61 patients were treated with triptorelin acetate. Height, weight, Tanner stage, BA, LH concentration, follicle-stimulating hormone (FSH) concentration, and testosterone concentration were evaluated every 6 months. The LH level was determined 30 min after GnRHa injection every 6 months during the treatment to monitor the suppression of the hypothalamic–pituitary–gonadal axis. LH level <3 IU/L was considered therapeutic suppression [11, 12]. Treatment was discontinued at the bone age of 13 to 13.5 years. Among the 85 boys, 20 boys were followed up after treatment discontinuation until achievement of the final adult height (FAH). We defined FAH as a height velocity of <1 cm/year and bone age >16.5 years [13].
Methods
Height was measured to the nearest 0.1 cm using a Harpenden stadiometer (Dong Sahn Jenix Co., Ltd., Seoul, South Korea). Weight was recorded to the nearest 0.1 kg using an electronic scale (Cas Co., Ltd., Seoul, South Korea). The volume of each testis was estimated by comparative palpation using a Prader orchidometer by a single pediatric endocrinologist [14]. Pubertal stage was determined by an experienced pediatric endocrinologist according to the method proposed by Marshall and Tanner [15]. Testicular volume was measured using the Prader orchidometer. Target height (TH) was the mean of the parental height plus 6.5 cm. BA was assessed by viewing a radiograph of the left hand and was determined by a single investigator according to the method proposed by Greulich and Pyle [16]. Predicted adult height (PAH) was calculated using the average tables in the Bayley–Pinneau method [17]. Standard deviation scores (SDS) of height, weight, and body mass index (BMI) were calculated using the 2017 growth reference for South Korean children and adolescents, provided by the Korean Pediatric Society and Korea Centers for Disease Control and Prevention [18]. A GnRH stimulation test (Relefact; Sanofi-Aventis, Frankfurt am Main, Germany) was performed. Serum FSH and LH levels were measured at baseline and at 30, 45, 60, and 90 min after administration of 100 μg GnRH. Serum LH and FSH levels were measured using Immunoradiometric Assay (BioSource SA, Nivelles, Belgium). Testosterone levels were determined using a radioimmunoassay, Coat-A-Count (Diagnostic Products, Los Angeles, CA, USA).
Ethics approval and consent to participate
The protocol was approved by the Institutional Review Board of Ajou University Hospital (AJIRB-MED-OBS-16-372). Written informed consent was obtained from all the subjects or their parents before FAH evaluation.
Statistical analysis
All statistical analyses were performed using SPSS (ver. 23.0, IBM Corp., Armonk, NY, USA). The values at treatment initiation and at treatment discontinuation were compared using a repeated-measures ANOVA test. Comparisons of the results between the groups were assessed using the independent t-test or Mann–Whitney U test, depending on the data distribution. To determine significant associations with the gain in height (the difference between the FAH and PAH at the initiation of treatment), univariate and multivariate analyses were performed with stepwise variable selection, including age at diagnosis, height SDS, TH, and duration of treatment. Statistical significance was set at p < 0.05. Results are presented as mean ± standard deviation, unless indicated otherwise.
Results
Patient characteristics
The mean age at diagnosis was 9.5 ± 0.5 years (range: 6.6–9.9 years). The mean duration of GnRHa treatment was 2.87 ± 0.63 years. The mean BA at the time of treatment initiation was 11.7 ± 0.9 years (Table 1). The peak serum LH and FSH levels after GnRH stimulation test were 15.0 ± 9.0 IU/L and 7.5 ± 4.1 IU/L, respectively.
Effect of GnRHa treatment
The changes in auxological outcomes are summarized in Table 1. After GnRHa treatment, the height SDS decreased significant, while weight and BMI SDS did not change significantly. Moreover, testicular volume decreased significantly during the treatment period. Serum LH levels 30 minutes after GnRHa in all subjects were <3 IU/L during treatment. During the treatment, the growth velocity was 5.71 ± 0.84 cm/year. The rate of growth was 6.27 ± 1.24 cm after 1 year of treatment, after which the growth rate tended to decrease gradually. The mean age and bone age at the time treatment discontinuation were 12.4 ± 0.5 and 13.5 ± 0.5 years, respectively.
There was a significant increase in the PAH after GnRHa treatment in boys with CPP. The PAH at treatment initiation was 172.1 ± 5.9 cm, while that at treatment discontinuation was 176.2 ± 6.6 cm (p < 0.001). The PAH at treatment discontinuation was significantly higher than the TH in boys with CPP.
Final adult height
Final auxological data were collected from 20 of 85 boys (Table 2). The final evaluation was performed at a mean age of 15.5 ± 1.4 years after a mean treatment duration of 2.73 ± 0.55 years. The mean final height was 173.4 ± 5.8 cm, and the final height increased significantly compared to the PAH at treatment initiation and the TH. However, there were no statistically significant differences between the FAH and PAH at treatment discontinuation (Fig 1).
*PAH, Predicted adult height; TH, target height; FAH, final adult height.
Of the 20 patients, 80% (n = 16) patients achieved a higher FAH than the PAH at treatment initiation. To identify the factors that determined the gain in height, which was defined as the difference between the FAH and PAH at treatment initiation, we divided the 20 boys into two groups—group A, FAH > PAH at treatment initiation (iPAH) (n = 16) and group B, FAH < iPAH (n = 4). We compared clinical variables such as age, height SDS, weight SDS BMI SDS, bone age, and PAH between the two groups. However, the variables were not significantly different between the two groups (data not shown).
Correlation
In the univariate analysis, the height gain (the difference between the FAH and iPAH) positively correlated with the TH. Moreover, multivariate analysis revealed that the gain in height was influenced significantly only by the TH in 20 boys with CPP who were followed up until achievement of the FAH (Table 3).
Discussion
In our study population, the PAH significantly increased by approximately 4.1 cm after GnRHa treatment in boys with CPP. The FAH was significantly higher than the iPAH and TH. Moreover, the TH was a strong determinant of the height gain.
Many studies in girls have reported that GnRHa treatment preserves or improves the growth potential in patients with CPP. However, limited data are available on the long-term outcomes of GnRHa treatment on growth in boys with CPP. Previous studies have demonstrated that untreated boys with CPP showed a FAH of approximately -3 standard deviations below the population average [19, 20]. Oerter et al. [21] reported the effect of deslorelin administered subcutaneously at a dose 4 μg/kg/day in 6 boys with CPP for the first time. They observed an improvement in the adult height compared to the pretreatment PAH, although the FAH was significantly lower than the TH by 10 cm. In a study by Paul et al. [20], the near final height in 6 boys treated with various GnRHa regimens was more than the height predicted before therapy. Partsch et al. [22] have suggested that boys with rapid pubertal development who are those likely to achieve below normal height need to be administered GnRHa treatment. Bertelloni and Mull [23] reviewed 11 published articles on the long-term outcomes of GnRHa treatment in 128 boys with CPP. They reported that the mean difference between the iPAH and FAH was -1.4–15.0 cm. Our study also showed that the FAH after GnRHa treatment increased by approximately 3.4 cm compared to the iPAH. However, these studies were conducted in a small number of subjects. Therefore, further studies with larger sample sizes are needed to validate the long-term effect of GnRHa in boys with CPP.
Several factors such as age at treatment initiation, duration of treatment, parental height, and height before treatment influence the growth outcomes after GnRHa treatment in patients with CPP. In our study, the TH was an important predictor, with better long-term growth outcome in 20 boys with CPP. Lazar et al. [24] reported the long-term growth outcomes in 115 girls with CPP and TH, SDS in height, bone age at treatment discontinuation, age at treatment initiation, and SDS of height at the onset of puberty were correlated with the FAH. In another study by Brito et al. [25], the major factors determining the FAH in girls with CPP were TH, SDS of height at treatment initiation and discontinuation, and shorter interval between the onset of puberty and treatment initiation. Oostdijk et al. [26] have reported that height at treatment initiation is the most important positive factor influencing the FAH. Paul et al. [20] have reported that boys with CPP treated before the CA of 5 years achieve a higher gain in height. BA at treatment initiation and discontinuation correlated with the FAH in a previous study in boys with CPP [26]. In another study on CPP, FAH significantly correlated with the duration of treatment, TH, iPAH, and growth velocity during the final year of treatment, while the FAH was inversely correlated with delay in treatment onset, CA at treatment initiation, BA at treatment initiation and discontinuation, and breast stage treatment initiation [27]. Recently, Klein et al. [28] have reported that the rate of change in the BA/CA ratio during GnRHa treatment positively correlated with the PAH in girls and boys with CPP.
Our study has several limitations. First, the number of subjects evaluated for the final height was relatively small. Second, we did not have untreated groups with CPP for ethical reasons. Third, PAH might have been overestimated in this study. Drop et al. [29] reported that the BP method tends to overestimate the FAH in tall boys. However, there are few studies on the validity of prediction methods based on BA in boys with CPP [9, 10]. Lastly, the mean age of patients with CPP in this study was >9 years. However, the determination of age at onset of puberty can be difficult in boys because the exact time of onset of testicular enlargement (≥4 mL) is not as obvious as breast enlargement in girls. Previous studies have reported that a mean delay between the time when the signs of puberty are first observed by the parents and the first consultation with an endocrinologist is 1.5 years [30, 31]. Owing to these difficulties, we included boys who were diagnosed with CPP before 10 years of age [32, 33].
In conclusion, GnRHa treatment can significantly improve the growth potential in boys with CPP. The FAH was significantly higher than the initial height prediction. The target height was the main factor determining the long-term growth outcome.
References
- 1. Carel JC, Leger J. Clinical practice. Precocious puberty. N Engl J Med. 2008;358(22):2366–77. Epub 2008/05/30. pmid:18509122.
- 2. Kaplowitz PB. Treatment of central precocious puberty. Curr Opin Endocrinol Diabetes Obes. 2009;16(1):31–6. Epub 2008/12/24. [pii]. pmid:19104235.
- 3. Wilson AC, Meethal SV, Bowen RL, Atwood CS. Leuprolide acetate: a drug of diverse clinical applications. Expert Opin Investig Drugs. 2007;16(11):1851–63. Epub 2007/11/01. pmid:17970643.
- 4. Partsch CJ, Heger S, Sippell WG. Management and outcome of central precocious puberty. Clin Endocrinol (Oxf). 2002;56(2):129–48. Epub 2002/03/05. 1490 [pii]. pmid:11874402.
- 5. Klein K, Yang J, Aisenberg J, Wright N, Kaplowitz P, Lahlou N, et al. Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty. J Pediatr Endocrinol Metab. 2016;29(11):1241–8. Epub 2016/02/18. pmid:26887034.
- 6. Blanco-Garcia M, Job JC, Chaussain JL, Canlorbe P. [Precocious puberty in boys. Study of a series of 34 cases]. Arch Fr Pediatr. 1983;40(8):637–42. Epub 1983/10/01. pmid:6418108.
- 7. Galluzzi F, Salti R, Bindi G, Pasquini E, La Cauza C. Adult height comparison between boys and girls with precocious puberty after long-term gonadotrophin-releasing hormone analogue therapy. Acta Paediatr. 1998;87(5):521–7. Epub 1998/06/26. pmid:9641733.
- 8. Rizzo V, De Sanctis V, Corrias A, Fortini M, Galluzzi F, Bertelloni S, et al. Factors influencing final/near-final height in 12 boys with central precocious puberty treated with gonadotrophin-releasing hormone agonists. Italian Study Group of Physiopathology of Puberty. J Pediatr Endocrinol Metab. 2000;13 Suppl 1:781–6. Epub 2000/09/02. pmid:10969921.
- 9. Mul D, Bertelloni S, Carel JC, Saggese G, Chaussain JL, Oostdijk W. Effect of gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty: final height results. Horm Res. 2002;58(1):1–7. Epub 2002/08/10. hre58001 [pii]. pmid:12169774.
- 10. Lazar L, Pertzelan A, Weintrob N, Phillip M, Kauli R. Sexual precocity in boys: accelerated versus slowly progressive puberty gonadotropin-suppressive therapy and final height. J Clin Endocrinol Metab. 2001;86(9):4127–32. Epub 2001/09/11. pmid:11549638.
- 11. Houk CP, Kunselman AR, Lee PA. The diagnostic value of a brief GnRH analogue stimulation test in girls with central precocious puberty: a single 30-minute post-stimulation LH sample is adequate. J Pediatr Endocrinol Metab. 2008;21(12):1113–8. Epub 2009/02/05. pmid:19189683.
- 12. Bhatia S, Neely EK, Wilson DM. Serum luteinizing hormone rises within minutes after depot leuprolide injection: implications for monitoring therapy. Pediatrics. 2002;109(2):E30. Epub 2002/02/05. pmid:11826240.
- 13. Lin YC, Lin CY, Chee SY, Yen HR, Tsai FJ, Chen CY, et al. Improved final predicted height with the injection of leuprolide in children with earlier puberty: A retrospective cohort study. PloS one. 2017;12(10):e0185080. Epub 2017/10/04. pmid:28973010; PubMed Central PMCID: PMC5626117.
- 14. Prader A. Testicular size: assessment and clinical importance. Triangle; the Sandoz journal of medical science. 1966;7(6):240–3. Epub 1966/01/01. pmid:5920758.
- 15. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child. 1970;45(239):13–23. Epub 1970/02/01. pmid:5440182; PubMed Central PMCID: PMC2020414.
- 16.
Greulich WW, Pyle SI. Radiologic atlas of skeletal development of the hand and wrist. 2nd ed. Standford: Stanford University Press; 1959.
- 17. Bayley N, Pinneau SR. Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. J Pediatr. 1952;40(4):423–41. Epub 1952/04/01. pmid:14918032.
- 18. Moon JS, Lee SY, Nam CM, Choi JM, Choe BK, Seo JW, et al. 2007 Korean National Growth Charts: review of developmental process and an outlook. Korean J Pediatr. 2008;51(1):1–25.
- 19. Sigurjonsdottir TJ, Hayles AB. Precocious puberty. A report of 96 cases. Am J Dis Child. 1968;115(3):309–21. Epub 1968/03/01. pmid:5640526.
- 20. Paul D, Conte FA, Grumbach MM, Kaplan SL. Long-term effect of gonadotropin-releasing hormone agonist therapy on final and near-final height in 26 children with true precocious puberty treated at a median age of less than 5 years. J Clin Endocrinol Metab. 1995;80(2):546–51. Epub 1995/02/01. pmid:7852518.
- 21. Oerter KE, Manasco P, Barnes KM, Jones J, Hill S, Cutler GB Jr., Adult height in precocious puberty after long-term treatment with deslorelin. J Clin Endocrinol Metab. 1991;73(6):1235–40. Epub 1991/12/11. pmid:1955504.
- 22. Partsch CJ, Heger S, Sippell WG. Treatment of central precocious puberty: lessons from a 15 years prospective trial. German Decapeptyl Study Group. J Pediatr Endocrinol Metab. 2000;13 Suppl 1:747–58. Epub 2000/09/02. pmid:10969917.
- 23. Bertelloni S, Mul D. Treatment of central precocious puberty by GnRH analogs: long-term outcome in men. Asian J Androl. 2008;10(4):525–34. Epub 2008/05/15. pmid:18478155.
- 24. Lazar L, Padoa A, Phillip M. Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity. J Clin Endocrinol Metab. 2007;92(9):3483–9. Epub 2007/06/21. pmid:17579199.
- 25. Brito VN, Latronico AC, Cukier P, Teles MG, Silveira LF, Arnhold IJ, et al. Factors determining normal adult height in girls with gonadotropin-dependent precocious puberty treated with depot gonadotropin-releasing hormone analogs. J Clin Endocrinol Metab. 2008;93(7):2662–9. Epub 2008/05/08. pmid:18460564.
- 26. Oostdijk W, Rikken B, Schreuder S, Otten B, Odink R, Rouwe C, et al. Final height in central precocious puberty after long term treatment with a slow release GnRH agonist. Arch Dis Child. 1996;75(4):292–7. Epub 1996/10/01. pmid:8984913; PubMed Central PMCID: PMC1511728.
- 27. Klein KO, Barnes KM, Jones JV, Feuillan PP, Cutler GB Jr., Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience. J Clin Endocrinol Metab. 2001;86(10):4711–6. Epub 2001/10/16. pmid:11600530.
- 28. Klein KO, Dragnic S, Soliman AM, Bacher P. Predictors of bone maturation, growth rate and adult height in children with central precocious puberty treated with depot leuprolide acetate. J Pediatr Endocrinol Metab. 2018;31(6):655–63. Epub 2018/05/12. pmid:29750651.
- 29. Drop SL, De Waal WJ, De Muinck Keizer-Schrama SM. Sex steroid treatment of constitutionally tall stature. Endocrine reviews. 1998;19(5):540–58. Epub 1998/10/30. pmid:9793756.
- 30. Teilmann G, Pedersen CB, Jensen TK, Skakkebaek NE, Juul A. Prevalence and incidence of precocious pubertal development in Denmark: an epidemiologic study based on national registries. Pediatrics. 2005;116(6):1323–8. Epub 2005/12/03. pmid:16322154.
- 31. Xhrouet-Heinrichs D, Lagrou K, Heinrichs C, Craen M, Dooms L, Malvaux P, et al. Longitudinal study of behavioral and affective patterns in girls with central precocious puberty during long-acting triptorelin therapy. Acta Paediatr. 1997;86(8):808–15. Epub 1997/08/01. pmid:9307158.
- 32. Yoon JS, So CH, Lee HS, Lim JS, Hwang JS. The prevalence of brain abnormalities in boys with central precocious puberty may be overestimated. PloS one. 2018;13(4):e0195209. Epub 2018/04/04. pmid:29614125; PubMed Central PMCID: PMC5882100.
- 33. Durand A, Bashamboo A, McElreavey K, Brauner R. Familial early puberty: presentation and inheritance pattern in 139 families. BMC endocrine disorders. 2016;16(1):50. Epub 2016/09/15. pmid:27624871; PubMed Central PMCID: PMC5022170.